Journal of Experimental & Clinical Cancer Research,
Journal Year:
2022,
Volume and Issue:
41(1)
Published: April 15, 2022
Abstract
Glioblastoma
(GBM)
is
the
most
common
high-grade
primary
malignant
brain
tumor
with
an
extremely
poor
prognosis.
Given
survival
currently
approved
treatments
for
GBM,
new
therapeutic
strategies
are
urgently
needed.
Advances
in
decades
of
investment
basic
science
glioblastoma
rapidly
translated
into
innovative
clinical
trials,
utilizing
improved
genetic
and
epigenetic
profiling
as
well
microenvironment
immune
system
interactions.
Following
these
encouraging
findings,
immunotherapy
including
checkpoint
blockade,
chimeric
antigen
receptor
T
(CAR
T)
cell
therapy,
oncolytic
virotherapy,
vaccine
therapy
have
offered
hope
improving
GBM
outcomes;
ongoing
studies
using
combinatorial
therapies
aim
minimizing
adverse
side-effects
augmenting
antitumor
responses.
In
addition,
techniques
to
overcome
blood-brain
barrier
(BBB)
targeted
delivery
being
tested
trials
patients
recurrent
GBM.
Here,
we
set
forth
rationales
promising
treating
review
potential
novel
agents,
current
status
preclinical
discuss
challenges
future
perspectives
immuno-oncology.
Journal of Clinical Investigation,
Journal Year:
2015,
Volume and Issue:
125(9), P. 3335 - 3337
Published: Aug. 31, 2015
The
recent
clinical
successes
of
immune
checkpoint
blockade
and
chimeric
antigen
receptor
T
cell
therapies
represent
a
turning
point
in
cancer
immunotherapy.
These
also
underscore
the
importance
understanding
basic
tumor
immunology
for
successful
translation
treating
patients
with
cancer.
Reviews
this
Review
Series
focus
on
current
developments
immunotherapy,
highlight
advances
our
aspects
immunology,
suggest
how
these
insights
can
lead
to
development
new
immunotherapeutic
strategies.
Nano Letters,
Journal Year:
2016,
Volume and Issue:
17(3), P. 1326 - 1335
Published: Nov. 23, 2016
The
induction
of
a
strong
cytotoxic
T
cell
response
is
an
important
prerequisite
for
successful
immunotherapy
against
many
viral
diseases
and
tumors.
Nucleotide
vaccines,
including
mRNA
vaccines
with
their
intracellular
antigen
synthesis,
have
been
shown
to
be
potent
activators
immune
response.
delivery
the
cytosol
presenting
cells
still
not
sufficiently
well
understood.
Here,
we
report
on
development
lipid
nanoparticle
formulation
induce
CD
8
We
show
transfection
dendritic
cells,
macrophages,
neutrophils.
efficacy
vaccine
was
tested
in
aggressive
B16F10
melanoma
model.
found
activation
after
single
immunization.
Treatment
tumors
nanoparticles
containing
coding
tumor-associated
antigens
gp100
TRP2
resulted
tumor
shrinkage
extended
overall
survival
treated
mice.
can
further
increased
by
incorporation
adjuvant
LPS.
In
conclusion,
presented
here
promising
vector
delivery,
one
that
capable
inducing
Further
optimization,
different
adjuvants,
will
likely
enhance
potency
vaccine.
